Indonesia Pharmaceuticals & Healthcare Report Q2 2015 - New Study Released

Indonesia's pharmaceutical market holds strong promise due to the continued expansion of universal healthcare and positive economic outlook with the ongoing integration of the country into the ASEAN Economic Community . However, this potential is weighed on by the newly passed law requiring halal certification , which is expected to be enforced by 2019.

Headline Expenditure Projections

* Pharmaceuticals: IDR63,806bn (USD6.11bn) in 2013 to IDR69,493bn (USD5.86bn) in 2014; +8.9% growth in local currency terms and -4.0% in US dollar terms. Forecast broadly in line with previous quarter.
* Healthcare: IDR284,975bn (USD27.3bn) in 2013 to IDR324,040bn (USD27.4bn) in 2014; +13.7% growth in local currency terms and +0.3% in US dollar terms.

Risk/Reward Index

In our latest Q414 proprietary Pharmaceutical Risk/Reward Index (RRI), Indonesia ranks 13th out of the 19 Asia Pacific markets. Though its Rewards are considered to be above than the regional average, Indonesia's Risks profile is considerably more unfavourable, which will continue to detract foreign players from investing in the country's pharmaceutical market.

Full Report Details at
- http://www.fastmr.com/prod/977513_indonesia_pharmaceuticals_healthcare_report_q2.aspx?afid=301

Key Trends And Developments

* In November 2014, employers in Indonesia requested that the new universal healthcare system be delayed by two years from the current January 1 2015 to January 1 2017. Deputy Chairman of the Indonesian Employers Association Hariyadi Sukamdani argued that this is to give enough time to perfect the country's healthcare system.
* In November 2014, Indonesian President Joko Widodo introduced the Indonesia Heath Card which is scheduled to be distributed across the country and provide free health insurance to the underprivileged. These cards will work similar to the Jakarta Health Card (KJS) that were launched in Jakarta when Widodo was its governor.
* In October 2014 the Halal Product Security (Jaminan Produk Halal) bill was signed into law by former President Susilo Bambang Yudhoyono. Originally mooted as a...

The Indonesia Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Indonesia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Indonesia pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Indonesia, to test other views - a key input for successful budgeting and strategic business planning in the Indonesian pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Bulgaria Pharmaceuticals & Healthcare Report Q2 2015
- South Korea Pharmaceuticals & Healthcare Report Q2 2015
- Peru Pharmaceuticals & Healthcare Report Q2 2015
- Nigeria Pharmaceuticals & Healthcare Report Q2 2015
- Mexico Pharmaceuticals & Healthcare Report Q2 2015